Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancerHIRSCH, Fred R; VARELLA-GARCIA, Marileila; VON PAWEL, Joachim et al.Journal of clinical oncology. 2006, Vol 24, Num 31, pp 5034-5042, issn 0732-183X, 9 p.Article

Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusionsDA SILVEIRA PASCHOALINI, Marcello; VARGAS, Francisco S; MARCHI, Evaldo et al.Chest. 2005, Vol 128, Num 2, pp 684-689, issn 0012-3692, 6 p.Article

Erlotinib in previously treated non-small-cell lung cancerSHEPHERD, Frances A; PEREIRA, José Rodrigues; VAN KOOTEN, Maximiliano et al.The New England journal of medicine. 2005, Vol 353, Num 2, pp 123-132, issn 0028-4793, 10 p.Article

Randomized Phase III Trial Comparing Bexarotene (L1069-49)/Cisplatin/Vinorelbine With Cisplatin/Vinorelbine in Chemotherapy-Naive Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer : SPIRIT IRAMLAU, Rodryg; ZATLOUKAL, Petr; ZHANG, Joseph K et al.Journal of clinical oncology. 2008, Vol 26, Num 11, pp 1886-1892, issn 0732-183X, 7 p.Article

Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non―Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2ZUKIN, Mauro; BARRIOS, Carlos H; DA ROCHA BALDOTTO, Clarissa Serodio et al.Journal of clinical oncology. 2013, Vol 31, Num 23, pp 2849-2853, issn 0732-183X, 5 p.Conference Paper

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyCIULEANU, Tudor; BRODOWICZ, Thomas; CUCEVIC, Branka et al.Lancet (British edition). 2009, Vol 374, Num 9699, pp 1432-1440, issn 0140-6736, 9 p.Article